NORTHSTAR NEUROSCIENCE ANNOUNCES FEASIBILITY STUDY OF ITS CORTICAL STIMULATION SYSTEM FOR TREATMENT-RESISTANT DEPRESSION

Northstar Neuroscience, Inc., a developer of medical devices for the treatment of neurological diseases and disorders, announced that the U. S. Food and Drug Administration (FDA) has granted approval for the company to conduct a clinical feasibility study of its cortical stimulation therapy system for the treatment of depression. The study will assess the safety and effectiveness of investigational cortical stimulation for patients diagnosed with major depressive disorder who are not responsive to other antidepressant treatments. Depression is a crippling disease that affects over 20 million people in the U.S., and it is estimated that 4 million of these do not respond to standard antidepressant treatments.
Genetic Engineering News